Abstract
Background:
A 29-year-old woman was diagnosed with lymph-node-positive, steroid-hormone-receptor-negative and HER2/neu-positive breast cancer. She underwent surgery followed by cyclophosphamide, epirubicin, and 5-fluorouracil chemotherapy, and received radiotherapy followed by trastuzumab therapy for 1 year. During the tenth month of trastuzumab therapy, the patient reported a missed period and had a positive pregnancy test.
Investigations:
Physical examination, pregnancy test, echocardiography.
Diagnosis:
Unintended pregnancy during adjuvant trastuzumab therapy.
Management:
Cessation of trastuzumab and close monitoring of mother and fetus during pregnancy.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / radiotherapy
-
Breast Neoplasms / surgery
-
Combined Modality Therapy
-
Cyclophosphamide / administration & dosage
-
Epirubicin / administration & dosage
-
Female
-
Fluorouracil / administration & dosage
-
Humans
-
Pregnancy
-
Pregnancy Complications, Neoplastic / diagnosis*
-
Pregnancy Complications, Neoplastic / drug therapy*
-
Receptor, ErbB-2 / metabolism
-
Receptors, Estrogen / metabolism
-
Receptors, Progesterone / metabolism
-
Trastuzumab
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Receptors, Estrogen
-
Receptors, Progesterone
-
Epirubicin
-
Cyclophosphamide
-
Receptor, ErbB-2
-
Trastuzumab
-
Fluorouracil